December 1-3, 2026 | Boston, MA

www.amylin-based-therapeutics.com

REGISTER BY FRIDAY, SEPTEMBER 11 TO SAVE UP TO $1,000

Amylin-Based Therapeutics Summit

Unlocking the Full Potential of Amylin Therapeutics

Deciphering Receptor Signaling, Efficacy-Tolerability Trade-off, and Optimal Amylin Mechanisms to Translate Amylin Biology into Differentiated, Clinically Meaningful Therapies

Expert Speakers Include:

Daniel Briere
Director
Eli Lilly

Kirsten Raun
Vice President, Scientific
Novo Nordisk

Andrew Young
Chief Scientific & Medical Officer
I2O Therapeutics

Thomas Lutz
Professor
University of Zurich

Cristina Rondinone
Chief Executive Officer
Pep2Tango

Gabriel Smolarz
Vice President
Zealand Pharma

Testimonial from the 3rd GLP-1 Based Therapeutics Summit:

"Amazing presentations, great networking, relevant content."

Harvest Moon Pharmaceuticals

+1 617 455 4188 info@hansonwade.com
www.amylin-based-therapeutics.com

hansonwade

Your Industry-Dedicated Forum to Unlock the Full Potential of Amylin Therapeutics

Amylin-Based Therapeutics Summit
December 1-3, 2026 | Boston, MA

Amylin development has moved beyond simply proving the mechanism works. With CagriSema nearing potential approval, Lilly advancing the selective agonist eloralintide, and debate intensifying over selective versus broader receptor engagement, the competitive challenge is now deciding what to build, how to translate it and where it will win. The inaugural Amylin-Based Therapeutics Summit is your opportunity to cut through the noise of broader obesity and diabetes meetings and spend 3 days dedicated entirely to amylin.

Join **50+ peers across receptor pharmacology, preclinical translation, clinical development and product strategy** to benchmark competing approaches and make real connections with the people actively shaping the next generation of metabolic therapeutics and beyond.

Across three days, pharma, biotech, and key opinion leaders will interrogate **receptor selectivity and signaling, compare fit-for-purpose models, reverse-translate clinical data, assess modality and exposure choices, and debate amylin as a standalone therapy versus a combination partner**. The result is a meeting designed to help teams make better development decisions while the field is still open enough for those decisions to shape best-in-class.

What Attendees of Events in the Series Have to Say

> The conference provided a unique opportunity to interact with individuals with a broad expertise in diverse areas relevant to optimizing treatment for those affected by obesity and related co-morbidities.

Executive Vice President, Medical Affairs, Aardvark Therapeutics

> The number of attendees was perfect. It allowed for more interactions and networking. The round tables and break activities also were beneficial for that purpose.

Global Senior VP, Product Development & Regulatory Affairs, Adipo Therpeutics

Cut Through the Noise: 3 Days Dedicated Entirely to Amylin R&D

Eloralintide Clinical Update

Hear how publicly available clinical evidence is shaping expectations for **selective amylin receptor agonism** and future development to inform your pipeline and program development and fast-track your candidate with lessons learned.

Lessons from Zenagamtide

Interrogate **dose-response, receptor balance and tolerability** as dual GLP-1/amylin agonism advances toward later-stage development and achieve clinical PoC.

Lessons from Petrelintide

Evaluate how selective amylin agonism is being positioned around **clinically meaningful weight loss** and tolerability, to understand how these attributes could support differentiation and inform future monotherapy and combination development strategies.

Decoding Receptor Specificity

Explore fully selective AMY1, AMY3 and calcitonin-receptor tools alongside G-protein and β-arrestin signalling to **move beyond trial-and-error design and achieve more rational, mechanism-led candidate selection** and optimization.

Receptor Architecture Deep Dive

Join peers in this three hour interactive session to challenge assumptions around receptor subtype importance, DACRA versus selective strategies, signaling bias and species translation, to **strengthen receptor-targeting decisions and reduce translational uncertainty** when designing next-generation amylin therapeutics.

+1 617 455 4188 info@hansonwade.com
www.amylin-based-therapeutics.com

What's Defining Amylin Drug Development in 2026?

Amylin-Based Therapeutics Summit
December 1-3, 2026 | Boston, MA

With a concentrated audience of amylin R&D leaders, networking is built into the meeting rather than left to chance. Across **five distinct formats - speed networking**, **interactive workshops**, **roundtable discussions**, **a Day 1 ice breaker**, **and the structured DACRA Debate** - attendees will have repeated opportunities to meet peers, exchange technical perspectives and build relationships around the scientific questions shaping the field. From rapid introductions to three-hour deep dives and small-group debate, each format is designed to create more meaningful conversations between the people actively advancing amylin therapeutics.

Key Sessions Not to Miss

A **LIGN** receptor-level biology with emerging human data to challenge assumptions before they become costly development decisions with **Novo Nordisk**

M **EASURE** leading clinical strategies across selective amylin agonism, dual GLP-1/amylin approaches and differentiated product profiles with **Eli Lilly**, **Novo Nordisk** & **Zealand Pharma**

Y **IELD** sharper decisions by comparing monotherapy and combination strategies to determine where amylin can create the greatest clinical and commercial value with **Pep2Tango**

L **EARN** how peptides, antibodies and oral small molecules compare across exposure, dosing, selectivity, manufacturability and intended patient use

I **NTERROGATE** the translational challenges shaping candidate selection, from species differences and receptor pharmacology to tolerability and body-composition outcomes

N **ETWORK** with a concentrated community of amylin specialists without competing for attention across a broad obesity or diabetes congress

Showcase Your Scientific Poster

Contribute to the conversation and share your cutting-edge research with your fellow amylin community to showcase your breakthrough discoveries to a vast audience of experts.

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Academic KOLs at the Cutting-Edge

Thomas Lutz, Professor, **University of Zurich**

Professor Thomas Lutz is Professor of Veterinary Physiology at the Institute of Veterinary Physiology, University of Zurich, Zurich, Switzerland. He graduated in veterinary medicine from the Free University of Berlin, Berlin, Germany, obtained his Dr. med. vet. from the Institute of Veterinary Physiology, University of Zurich and a PhD from the University of Queensland, Brisbane, Australia. Professor Lutz was the Head of Research Group and then Professor for Applied Veterinary Physiology at the Institute of Veterinary Physiology before becoming Professor of Veterinary Physiology in 2008. He is also the Director of the Steering Committee of the One Health Institute, University of Zurich. Professor Lutz has published 280 articles in scientific journals.

Debbie Hay, Professor, Pharmacology, **Otago University**

Debbie Hay is Professor of Pharmacology at the University of Otago, where her research focuses on G protein-coupled receptors, particularly class B GPCRs and receptor activity-modifying proteins. Her work spans pharmacology, structural biology, peptide chemistry and molecular biology, with a strong focus on migraine therapeutics. A highly cited researcher and Fellow of the British Pharmacological Society, Debbie also chairs the NC-IUPHAR subcommittee on CGRP peptide family receptor nomenclature and is an active mentor of early-career researchers.

Augen Pioszak, Associate Professor, Department of Biochemistry & Physiology, **University of Oklahoma**

Augen Pioszak is an Assistant Professor of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center. His research focuses on the structural biology and pharmacology of G protein-coupled receptors, including NIH-funded work on RAMP-altered class B GPCR hormone recognition. Trained in biochemistry, signal transduction and X-ray crystallography, he completed postdoctoral fellowships at RIKEN and the Van Andel Research Institute. His laboratory has published across leading journals including Molecular Cell, Journal of Biological Chemistry and Molecular Pharmacology.

+1 617 455 4188 info@hansonwade.com
www.amylin-based-therapeutics.com
hansonwade

Your Expert Speakers

Pharma Leaders Driving Discovery to Clinical Strategy

Anna Secher
Director, Scientific
Novo Nordisk

Kirsten Raun
Vice President, Scientific
Novo Nordisk

Gabriel Smolarz
Vice President, US Medical Affairs & Medical Advisor
Zealand Pharma

Daniel Briere
Senior Director
Eli Lilly

Biotech Innovators Advancing Next-Generation Amylin Therapies

Cody Moore
Director, Platform Development
iBio

Martin Brenner
Chief Executive Officer & Chief Scientific Officer
iBio

Andrew Young
Chief Scientific & Medical Officer
I2O Therapeutics

Ved Srivastava
Chief Scientific Officer
Perpetual Medicines

Cristina Rondinone
Founder & Chief Executive Officer
Pep2Tango

Brent Meadows
Chief Business Officer
Senovia Biosciences

Mads Tang-Christensen
Chief Scientific Officer
Antag Therapeutics

Alice Fitzpatrick
Director, Gene Therapy
Fractyl Laboratories

Bin Zhu
Vice President, Business Development
GeneScience Pharmaceuticals

Academics & Investors Translating Science into Clinical Impact

Thomas Lutz
Professor
University of Zurich

Augen Pioszak
Associate Professor, Department of Biochemistry & Physiology
University of Oklahoma

Debbie Hay
Professor, Pharmacology
Otago University

Jay Olson
Research Analyst
Oppenheimer & Company

Pre-Conference Workshop Day
Tuesday, December 1

Check In, Coffee & Light Breakfast — 8.00 - 9.00

Workshop A — 9.00 – 12.00

Decoding Amylin Receptor Architecture, Ligand Engagement & Signaling

This workshop addresses the field's most pressing challenge: determining optimal receptor targeting strategies. The session will explore the complex receptor system (amylin I, II, III, and calcitonin receptors), examining the debate between amylin-selective versus dual amylin-calcitonin receptor agonist (DACRA) approaches. Participants will analyze preclinical data from rats suggesting amylin III importance versus emerging human data showing different profiles, discuss the lack of translatable antibodies to RAMPs limiting receptor distribution mapping, and evaluate signaling bias (beta-arrestin vs G-protein pathways) and its impact on efficacy and tolerability.

What attendees will gain:

Attendees will leave with a framework for evaluating receptor selectivity strategies, understanding the trade-offs between precision targeting and broad receptor coverage, and insights into how receptor profiles may predict clinical outcomes.

Key questions to be addressed:

- Which amylin receptor subtype (I, II, or III) is most critical for weight loss efficacy in humans, and how does this differ from rodent models?
- Should next-generation therapeutics target amylin receptors selectively or employ a DACRA approach, and what are the mechanistic rationales for each strategy?
- How does signaling bias (beta-arrestin vs G-protein recruitment) influence tolerability, efficacy, and quality of weight loss?
- What tools and methodologies are needed to definitively map receptor distribution in human brain and peripheral tissues?
- How can we overcome the species translation challenge when rodent receptor profiles don't match human profiles?

Workshop Leader

Thomas Lutz
Professor
University of Zurich

Lunch Break & Networking — 12.00 – 1.00

> "The topics were great and some speakers were excellent and accessible"
>
> Senior Director, Quantitative Pharmacology & Pharmacometrics, **Merck**
>
> *Testimonial from the 3rd GLP-1 Based Therapeutics Summit*

Pre-Conference Workshop Day
Tuesday, December 1

Workshop B 1.00 - 4.00

Navigating the Efficacy-Tolerability Trade-Off - Linking Half-Life, Dosing & Clinical Outcomes to Define Amylin's Competitive Advantage

This workshop tackles the fundamental question of where amylin therapeutics fit in the treatment landscape relative to GLP-1s. Participants will examine clinical readouts comparing amylin analogs to incretins, analyzing whether improved tolerability profiles allow higher dosing and greater efficacy. The session will explore the relationship between half-life and both efficacy and tolerability, discussing whether longer-acting molecules provide smoother pharmacokinetics with reduced GI side effects. Critical focus will be placed on patient populations: Do non-responders to GLP-1s respond better to amylins? Can amylins serve as maintenance therapy post-GLP-1 weight loss? The workshop will integrate preclinical biology with clinical data to understand how molecular design translates to patient outcomes.

What attendees will gain:

Attendees will develop strategies for positioning amylin therapeutics in clinical development, understanding patient segmentation opportunities, and designing molecules that optimize the efficacy-tolerability balance.

Key questions to be addressed:

- Do patients who don't respond to or can't tolerate GLP-1s respond better to amylin-based therapeutics?
- How does half-life influence the efficacy-tolerability trade-off, and what is the optimal pharmacokinetic profile?
- Can amylins deliver better quality weight loss (lean mass preservation, reduced weight rebound) compared to GLP-1s?
- What is the ideal patient segmentation strategy for amylin therapeutics (first-line, second-line, maintenance, specific populations)?
- How do we link in vitro receptor pharmacology and in vivo preclinical data to predict clinical tolerability and efficacy?

Workshop Leader

Martin Brenner
Chief Executive & Scientific Officer
iBio

End of Pre-Conference Workshop Day 4.00

> "Presentations covered the most relevant topics regarding GLP1s. Excellent networking opportunities. Helpful host companies"
>
> Chief Executive Officer, **Harvest Moon Pharmaceuticals**
>
> *Testimonial from the 3rd GLP-1 Based Therapeutics Summit*

Conference Day One
Wednesday, December 2

8.00 **Check In, Coffee & Light Breakfast**

Thomas Lutz
Professor
University of Zurich

8.45 **Chair's Opening Remarks**

8.50 **Ice Breaker**

Kick off the summit by getting to know the people at your table. Each attendee will have the opportunity to briefly introduce themselves, share their role and current focus in amylin R&D, and identify the challenges they are most interested in discussing - making it easier to spot relevant peers, start conversations early and build stronger connections throughout the meeting.

From Amylin Discovery to the Current Phase II Clinical Progress to Define Amylin's Efficacy, Tolerability & Differentiation Potential

Andrew Young
Chief Scientific & Medical Officer
I2O Therapeutics

9.00 **From Pancreatic Amyloid to Therapeutic Hormone: Lessons from the Discovery & Development of Amylin**

- Trace the evolution of amylin from its discovery within pancreatic amyloid deposits to recognition as a co-secreted metabolic hormone, revealing how changing biological understanding transformed an apparent marker of disease into a viable therapeutic target
- Review the foundational pharmacology that established amylin's roles in satiety, gastric emptying, glucagon regulation and nutrient control, highlighting the experiments and translational decisions that enabled development of the first amylin-mimetic medicines
- Reflect on the scientific and development lessons from Amylin Pharmaceuticals, including receptor uncertainty, peptide stability and formulation challenges, to identify what today's developers should retain, or reconsider, when engineering the next generation of amylin therapeutics

Ved Srivastava
Chief Scientific Officer
Perpetual Medicines

9.30 **Modern Amylin Molecules: Beyond Fibrillation Toward Developable Therapeutics**

- Review how early fibrillation challenges were addressed through sequence modification and alternative peptide backbones
- Examine the remaining trade-offs between stability, aggregation, receptor pharmacology, concentration, formulation and manufacturability
- Separate developability challenges of therapeutic analogues from the biological significance of endogenous amylin aggregation in diabetes and other diseases

10.00 **Speed Networking**

A prime chance to make the most of in-person networking and forge new connections as new companies enter and existing ones broaden their presence within the amylin space. This is designed to maximize your exposure to a wide range of new individuals and serve as a catalyst for ongoing discussions throughout the summit.

10.45 **Morning Break & Refreshments**

Daniel Briere
Senior Director
Eli Lilly

11.00 **Session Reserved for Eli Lilly's Eloralintide**

+1 617 455 4188 info@hansonwade.com
www.amylin-based-therapeutics.com

Conference Day One
Wednesday, December 2

Kirsten Raun
Scientific Vice President
Novo Nordisk

11.30 Translating Dual GLP-1/Amylin Agonism into Meaningful Glycaemic Control & Weight Loss: Lessons from Zenagamtide

- Examine the Phase II dose-response findings for once-weekly zenagamtide, including HbA1c reductions of up to 1.71 percentage points and body-weight loss of up to 14.6% at 36 weeks, to assess the clinical potential of combining GLP-1 and amylin receptor agonism within a single molecule
- Explore how dose escalation, receptor balance and exposure influenced efficacy and gastrointestinal tolerability, enabling developers to refine therapeutic windows and make more informed dose-selection decisions for next-generation co-agonists
- Translate the findings into future development strategy, from identifying the patient populations most likely to benefit to determining how dual GLP-1/amylin assets can differentiate from established incretins as zenagamtide advances toward Phase III development

Gabriel Smolarz
Vice President
Zealand Pharma

12.00 Balancing Clinically Meaningful Weight Loss with Placebo-Like Tolerability: Phase II Lessons from Petrelintide

- Evaluate how once-weekly petrelintide achieved up to 10.7% mean weight loss at 42 weeks while maintaining a tolerability profile comparable to placebo, demonstrating the potential for selective amylin agonism to deliver sustained efficacy without the gastrointestinal burden commonly associated with obesity therapies
- Examine how four-week dose escalation supported high maintenance-dose attainment, minimal nausea after titration and no vomiting at the maximally effective dose, providing practical insight into how dosing strategy can optimize adherence and the efficacy–tolerability balance
- Explore how sex-based differences, body-composition outcomes and petrelintide's fibrillation-resistant design can inform Phase III development and combination strategy, enabling developers to identify responsive populations and position amylin as both a differentiated monotherapy and a complementary partner to other metabolic mechanisms

12.30 Lunch & Networking Break

Reverse-Translating Clinical Insight & Strengthening Receptor-Level Tools to Guide Next-Generation Amylin Design

Cody Moore
Director, Platform Development
iBio

1.30 Decoding Amylin Receptor Specificity to Engineer a More Precise, Long-Acting Therapeutic

- Explore how fully selective antibodies can distinguish between AMY1, AMY3 and calcitonin receptor activity, moving beyond broadly biased peptide agonists to identify which receptor profiles drive weight loss, tolerability and body-composition outcomes
- Examine how parallel interrogation of G-protein and β-arrestin signaling can connect cellular mechanism with in vivo performance, enabling more rational optimization of potency, signaling bias and receptor engagement rather than relying on clinical trial-and-error
- Assess the potential of ultra-long-acting amylin antibodies to deliver infrequent dosing, sustained receptor coverage and improved treatment adherence, helping developers pursue durable efficacy while reducing adverse effects, treatment burden and weight cycling

Conference Day One
Wednesday, December 2

Augen Pioszak
Associate Professor, Department of Biochemistry & Physiology
University of Oklahoma

2.00 **Resolving the Pharmacology of Individual Amylin Receptor Heterodimers**

- Expose how conventional cAMP assays generate composite signals from mixed populations of free calcitonin receptors and amylin receptor heterodimers, obscuring the true activity of individual ligands
- Introduce new assays capable of distinguishing AMY1, AMY2 and AMY3 heterodimers within mixed receptor populations, enabling direct pharmacological characterisation of each receptor subtype
- Examine how different ligands influence receptor-subunit association, dissociation and signalling dynamics, revealing functional differences between the three amylin receptor complexes
- Explore how receptor-specific pharmacology and signalling kinetics could ultimately be linked with clinical efficacy and tolerability to support rational ligand design

2.30 **Afternoon & Break & Scientific Poster Session**

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in amylin research and advancements.
To submit a poster, please contact info@hansonwade.com

Anna Secher
Director, Scientific
Novo Nordisk

3.30 **Reverse-Translating Clinical Readouts to Refine the Next Generation of Amylin Therapeutics**

- Compare emerging efficacy, tolerability, titration and discontinuation patterns across selective amylin agonists, balanced agonists and amylin-containing combinations, distinguishing molecule-specific effects from potential class effects
- Interrogate whether current clinical performance supports proposed hypotheses around receptor selectivity, exposure, signalling bias and dose escalation, identifying which mechanistic assumptions require revision
- Translate clinical successes and disappointments back into preclinical decision-making, enabling earlier programs to update target product profiles, assays and candidate-selection criteria before entering costly trials

4.00 **Roundtable Discussion: Designing the Right Clinical Trial Strategy for Amylin Therapeutics**

- Compare how developers are approaching patient selection, from GLP-1 non-responders and intolerant patients to first-line treatment populations
- Debate which endpoints beyond headline weight loss will be most valuable, including body composition, metabolic outcomes, quality of life and weight maintenance
- Discuss when placebo remains appropriate versus when active GLP-1 comparators are needed to demonstrate meaningful differentiation
- Share how trial design should evolve across monotherapy, combination strategies and different intended product profiles

Debbie Hay
Professor, Pharmacology
Otago University

5.00 **Learning from the CGRP Field to Advance Amylin Receptor Pharmacology**

- Compare amylin and CGRP receptor architecture, shared RAMP biology, expression and challenges in assigning ligand selectivity
- Apply lessons from CGRP assay development, nomenclature and receptor characterisation to improve consistency in the amylin field
- Identify where decades of CGRP drug development can inform target validation, translational pharmacology and therapeutic differentiation

Thomas Lutz
Professor
University of Zurich

5.30 **Chair's Closing Remarks**

Conference Day Two
Thursday, December 3

8.30 Check In, Coffee & Light Breakfast

Alice Fitzpatrick
Director, Gene Therapy
Fractyl Laboratories

9.25 **Chair's Opening Remarks**

Defining Differentiated Weight-Loss Quality & Optimizing Amylin Across Monotherapy, Combination & Exposure Strategies

Mads Tang-Christensen
Chief Scientific Officer
Antag Therapeutics

9.30 **Unlocking GIP Receptor Antagonism as an Amylin Sensitizer for Next-Generation Cardiometabolic Therapy**

- Establish GIP receptor antagonism as a foundational cardiometabolic mechanism, exploring effects beyond appetite suppression and the potential for independent improvements across glycaemic control, lipid metabolism and body composition
- Demonstrate how GIPR antagonism can sensitize complementary nutrient-stimulated hormone pathways, examining the rationale for combining AT-7687 with GLP-1 and amylin-based therapies to enhance efficacy without compounding tolerability
- Translate human genetics and preclinical combination evidence into an amylin strategy, leveraging data showing synergy between GIPR antagonism and dual amylin/calcitonin receptor agonism in translational models to inform rational next-generation combinations

Cristina Rondinone
Chief Executive Officer & Founder
Pep2Tango

10.00 **Defining & Measuring the Quality of Amylin-Induced Weight Loss**

- Compare methods for measuring fat mass, lean mass, visceral and subcutaneous adipose tissue, bone and broader metabolic changes
- Determine which measurements can be aligned from preclinical models through clinical trials to support meaningful comparison
- Establish what evidence would be needed to demonstrate that any body-composition benefit is specific to a molecule, mechanism or receptor profile

10.30 **DACRA Debate – Challenge the Evidence Behind Broad vs Selective Receptor Targeting to Strengthen Next-Generation Amylin Design**

Take part in a structured networking debate exploring one of the field's most important strategic questions: broad dual amylin/calcitonin receptor agonism versus more selective amylin receptor targeting. Compare the scientific rationale, translational evidence and perceived trade-offs behind each approach, challenge assumptions with peers, and build connections with developers working across both sides of the debate.

11.00 Morning Break & Refreshments

Defining the Amylin Patient & Designing Clinical Development for Real-World Adoption and Long-Term Persistence

Brent Meadows
Chief Business Officer
Senovia Biosciences

11.30 **Horizon Scanning Roundtable: Where Could Amylin Biology Create Value Beyond Metabolic Disease?**

- Investigating amylin's potential in type 1 diabetes for glycemic control and hypoglycemia reduction
- Examining metabolic benefits for MASH, kidney disease, and cardiovascular outcomes
- Discussing speculative but intriguing indications: addiction, alcohol use disorder, sleep disorders, and Alzheimer's disease

Conference Day Two
Thursday, December 3

Bin Zhu
Vice President, Business Development
GeneScience Pharmaceuticals

12.00 The Investor Lens on Amylin: Where Will Capital Flow in the Next Wave of Obesity Innovation?

- Assess what is driving investor conviction in amylin, from major pharma prioritisation and billion-dollar partnering activity to growing interest in preclinical assets, and determine whether the field represents the next major investment cycle after GLP-1s
- Define what makes an amylin company or asset investable, examining which differentiators - efficacy, tolerability, receptor profile, oral or long-acting delivery, combination potential and quality of weight loss - are most likely to justify financing and strategic interest as the competitive landscape expands
- Explore how investors should balance opportunity against scientific risk, identifying the clinical and translational milestones needed to de-risk programmes, where there is still whitespace for new entrants, and when partnering, acquisition or continued independent development creates the greatest value

12.30 Lunch & Networking Break

Defining Amylin's Clinical Value & Building the Investment Case for Future Growth

1.30 Roundtable Discussion: Who Is the Amylin Patient, & What Will Make Clinicians Choose It?

- Identify where amylin may offer a meaningful alternative for patients prioritizing tolerability, gradual weight loss, lower-BMI intervention or a different treatment experience
- Examine its potential use after incretin intolerance, inadequate response, treatment plateau or discontinuation without assuming these groups are already clinically defined
- Determine what evidence clinicians need to distinguish between amylin, incretins and combinations in individual patients
- Develop practical scenarios for initiation, switching, sequencing, add-on treatment and maintenance

Jay Olson
Research Analyst
Oppenheimer & Company

2.30 Navigating the Funding Landscape to Accelerate Indication-Agnostic Amylin R&D

- Gain insight into where investor appetite is building across selective agonists, combination approaches, oral molecules, antibodies and long-acting amylin strategies
- Understand the key financing stages from seed and Series A through clinical development, strategic partnerships and late-stage capital
- Identify the scientific and clinical milestones investors need to see to de-risk amylin programmes and support the next funding round
- Learn how to articulate a differentiated value proposition around receptor strategy, efficacy, tolerability, modality, patient positioning and indication expansion to attract investment and strategic partners

Alice Fitzpatrick
Director, Gene Therapy
Fractyl Laboratories

3.00 Chair's Closing Remarks & End of Conference

Partner With Us

Amylin-Based Therapeutics Summit
December 1-3, 2026 | Boston, MA

Your Global Platform to Build Strategic Partnerships & Expand Your Network Across the Rapidly Building Amylin Therapeutics Landscape

The amylin drug development landscape is entering a critical phase of expansion. As developers advance increasingly diverse strategies across selective amylin agonists, DACRAs, long-acting peptides, antibodies, oral small molecules and combination approaches, they are facing persistent challenges around receptor biology, species translation, efficacy–tolerability trade-offs, body-composition outcomes, clinical trial design and product differentiation.

To overcome these hurdles, biopharma teams are increasingly looking beyond their internal capabilities and seeking specialist partners who can help them generate:

- More predictive preclinical data
- Select fit-for-purpose models
- Characterize receptor engagement
- Measure fat versus lean mass
- Identify translational biomarkers
- Optimize clinical recruitment

The **Amylin-Based Therapeutics Summit** provides a unique opportunity to position your expertise in front of the discovery, preclinical, translational and clinical leaders actively shaping the next generation of amylin programs. Whether your organization provides preclinical CRO services, rat models, imaging, biomarker technologies or clinical trial support, this is your opportunity to engage directly with developers working across obesity, diabetes, MASH and other emerging indications who are actively searching for solutions to the field's most pressing development challenges.

Enter The Next Metabolic Buying Cycle Early

Amylin programs are expanding across obesity, diabetes and adjacent cardiometabolic indications. Partner now to build relationships with teams making model, assay, imaging, biomarker and clinical outsourcing decisions before supplier relationships become entrenched.

Solve The Gaps Developers Cannot Efficiently Build In-House

Research for the summit repeatedly highlighted missing amylin-specific tools: limited RAMP antibodies, incomplete screening platforms, species-translation uncertainty and a need for better ways to measure fat, lean mass and organ-level outcomes. Position your solution directly against these active bottlenecks.

Expand Beyond Your Existing Glp-1 Network

Reach an indication-agnostic R&D community working across amylin monotherapy, combinations and emerging applications. The focused format creates more time with scientific decision-makers than a broad obesity trade show, while giving you visibility across discovery, preclinical, translational and clinical teams.

Seniority of Attendees

- CXO: 35%
- Vice President: 9%
- Director: 20%
- Head: 3%
- Scientist: 6%
- Manager: 9%
- Other: 14%

Type of Companies Attending



- Pharma
- Biotech
- Research Institutes
- Academic

Statistics Taken from the 4th Obesity & Weight Loss Drug Development Summit

Get Involved

Connor Drake
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.amylin-based-therapeutics.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

DECODE the receptor biology behind clinical performance by connecting selectivity, signaling, species translation and receptor-specific tools with the latest development experience.

BENCHMARK how leading developers are approaching monotherapy versus combination, modality, exposure, titration, trial design and patient positioning to identify where your program can genuinely differentiate.

CONNECT with a concentrated community spanning foundational amylin KOLs, leading pharma, emerging biotech and cross-functional R&D leaders in a format built for candid technical exchange and meaningful relationship-building.

Present a Poster
Contribute to the conversation and share your cutting-edge research with your fellow amylin community to showcase your breakthrough discoveries to a vast audience of experts.
Register your place to submit an abstract for review to showcase your poster*
*Please visit the website for the T&Cs for presenting a poster

Drug Developers	Register by Friday, September 11 to Save Up to $1,000	On the Door Price
Conference + 2 Workshops	$3,397	$4,397
Conference + 1 Workshop	$2,998	$3,748
Conference Only	$2,599	$3,099
Academic & Research Institutes**	Register by Friday, September 11 to Save Up to $1,000	On the Door Price
Conference + 2 Workshops	$2,797	$3,797
Conference + 1 Workshop	$2,498	$3,248
Conference Only	$2,199	$2,699
Solution & Service Providers	Register by Friday, September 11 to Save Up to $1,000	On the Door Price
Conference + 2 Workshops	$4,297	$5,297
Conference + 1 Workshop	$3,798	$4,548
Conference Only	$3,299	$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Wyndham Boston Beacon Hill
5 Blossom St, Boston, MA 02114, United States
https://www.wyndhambeaconhill.com/